212 related articles for article (PubMed ID: 16236036)
1. Pharmacokinetics of insulin aspart in obesity, renal impairment, or hepatic impairment.
Holmes G; Galitz L; Hu P; Lyness W
Br J Clin Pharmacol; 2005 Nov; 60(5):469-76. PubMed ID: 16236036
[TBL] [Abstract][Full Text] [Related]
2. Obesity does not influence the unique pharmacological properties of different biphasic insulin aspart preparations in patients with type 2 diabetes.
Parkner T; Dyrskog SE; Laursen T; Chen JW; Mouritzen U; Brondsted L; Hermansen K; Lauritzen T; Christiansen JS
Diabetes Obes Metab; 2010 May; 12(5):414-20. PubMed ID: 20415689
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacodynamic and pharmacokinetic characteristics of subcutaneous insulin glulisine and insulin aspart prior to a standard meal in obese subjects with type 2 diabetes.
Bolli GB; Luzio S; Marzotti S; Porcellati F; Sert-Langeron C; Charbonnel B; Zair Y; Owens DR
Diabetes Obes Metab; 2011 Mar; 13(3):251-7. PubMed ID: 21205115
[TBL] [Abstract][Full Text] [Related]
4. Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron.
Dickinson J; Lewand M; Sawamoto T; Krauwinkel W; Schaddelee M; Keirns J; Kerbusch V; Moy S; Meijer J; Kowalski D; Morton R; Lasseter K; Riff D; Kupčová V; van Gelderen M
Clin Drug Investig; 2013 Jan; 33(1):11-23. PubMed ID: 23208320
[TBL] [Abstract][Full Text] [Related]
5. A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.
Ma Z; Parkner T; Frystyk J; Laursen T; Lauritzen T; Christiansen JS
Diabetes Technol Ther; 2012 Jul; 14(7):589-95. PubMed ID: 22519735
[TBL] [Abstract][Full Text] [Related]
6. A comparison of pharmacokinetics and pharmacodynamics of biphasic insulin aspart 30, 50, 70 and pure insulin aspart: a randomized, quadruple crossover study.
Thorisdottir RL; Parkner T; Chen JW; Ejskjaer N; Christiansen JS
Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):216-21. PubMed ID: 19175369
[TBL] [Abstract][Full Text] [Related]
7. The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil.
Muirhead GJ; Wilner K; Colburn W; Haug-Pihale G; Rouviex B
Br J Clin Pharmacol; 2002; 53 Suppl 1(Suppl 1):21S-30S. PubMed ID: 11879256
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
9. Asenapine pharmacokinetics in hepatic and renal impairment.
Peeters P; Bockbrader H; Spaans E; Dogterom P; Lasseter K; Marbury T; Gibson GL; de Greef R
Clin Pharmacokinet; 2011 Jul; 50(7):471-81. PubMed ID: 21651314
[TBL] [Abstract][Full Text] [Related]
10. Improved postprandial glycaemic control with insulin Aspart in type 2 diabetic patients treated with insulin.
Rosenfalck AM; Thorsby P; Kjems L; Birkeland K; Dejgaard A; Hanssen KF; Madsbad S
Acta Diabetol; 2000 Mar; 37(1):41-6. PubMed ID: 10928235
[TBL] [Abstract][Full Text] [Related]
11. Time-action profile and patient assessment of inhaled insulin via the Exubera device in comparison with subcutaneously injected insulin aspart via the FlexPen device.
Forst T; Hohberg C; Schöndorf T; Borchert M; Forst S; Roth W; Dehos B; Pfützner A
Diabetes Technol Ther; 2009 Feb; 11(2):87-92. PubMed ID: 19848574
[TBL] [Abstract][Full Text] [Related]
12. Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.
Jovanovic L; Giammattei J; Acquistapace M; Bornstein K; Sommermann E; Pettitt DJ
Clin Ther; 2004 Sep; 26(9):1492-7. PubMed ID: 15531011
[TBL] [Abstract][Full Text] [Related]
13. The effects of degree of hepatic or renal impairment on the pharmacokinetics of exemestane in postmenopausal women.
Jannuzzo MG; Poggesi I; Spinelli R; Rocchetti M; Cicioni P; Buchan P
Cancer Chemother Pharmacol; 2004 Jun; 53(6):475-81. PubMed ID: 15014897
[TBL] [Abstract][Full Text] [Related]
14. Effects of hepatic or renal impairment on the pharmacokinetics of aripiprazole.
Mallikaarjun S; Shoaf SE; Boulton DW; Bramer SL
Clin Pharmacokinet; 2008; 47(8):533-42. PubMed ID: 18611062
[TBL] [Abstract][Full Text] [Related]
15. Comparative pharmacokinetics and pharmacodynamics of the novel rapid-acting insulin analogue, insulin aspart, in healthy volunteers.
Home PD; Barriocanal L; Lindholm A
Eur J Clin Pharmacol; 1999 May; 55(3):199-203. PubMed ID: 10379635
[TBL] [Abstract][Full Text] [Related]
16. Insulin aspart (B28 asp-insulin): a fast-acting analog of human insulin: absorption kinetics and action profile compared with regular human insulin in healthy nondiabetic subjects.
Mudaliar SR; Lindberg FA; Joyce M; Beerdsen P; Strange P; Lin A; Henry RR
Diabetes Care; 1999 Sep; 22(9):1501-6. PubMed ID: 10480516
[TBL] [Abstract][Full Text] [Related]
17. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
Lindholm A; Jacobsen LV
Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics and pharmacodynamics of insulin aspart, a rapid-acting analog of human insulin, in healthy Japanese volunteers.
Kaku K; Matsuda M; Urae A; Irie S
Diabetes Res Clin Pract; 2000 Aug; 49(2-3):119-26. PubMed ID: 10963823
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and imaging properties of Gd-EOB-DTPA in patients with hepatic and renal impairment.
Gschwend S; Ebert W; Schultze-Mosgau M; Breuer J
Invest Radiol; 2011 Sep; 46(9):556-66. PubMed ID: 21623212
[TBL] [Abstract][Full Text] [Related]
20. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan.
Hirao K; Maeda H; Urata S; Takisawa Y; Hirao S; Sasako T; Sasaki T
Clin Ther; 2007 May; 29(5):927-934. PubMed ID: 17697911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
